High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure

Jean-Pierre Frat, M.D., Arnaud W. Thille, M.D., Ph.D., Alain Mercat, M.D., Ph.D., Christophe Girault, M.D., Ph.D., Stéphanie Ragot, Pharm.D., Ph.D., Sébastien Perbet, M.D., Gwénaël Prat, M.D., Thierry Boulain, M.D., Elise Morawiec, M.D., Alice Cottereau, M.D., Jérôme Devaquet, M.D., Saad Nseir, M.D., Ph.D., Keyvan Razazi, M.D., Jean-Paul Mira, M.D., Ph.D., Laurent Argaud, M.D., Ph.D., Jean-Charles Chakarian, M.D., Jean-Damien Ricard, M.D., Ph.D., Xavier Wittebole, M.D., Stéphanie Chevalier, M.D., Alexandre Herbland, M.D., Muriel Fartoukh, M.D., Ph.D., Jean-Michel Constantin, M.D., Ph.D., Jean-Marie Tonnelier, M.D., Marc Pierrot, M.D., Armelle Mathonnet, M.D., Gaétan Béduneau, M.D., Céline Delétage-Métreau, Ph.D., Jean-Christophe M. Richard, M.D., Ph.D., Laurent Brochard, M.D., and René Robert, M.D., Ph.D., for the FLORALI Study Group and the REVA Network*

ABSTRACT

The authors’ affiliations are listed in the Appendix. Address reprint requests to Dr. Frat at Centre Hospitalier Universitaire de Poitiers, Service de Réanimation Médicale 2, rue de la Milétrie, CS 90577, 86021 CEDEX Poitiers, France, or at jean-pierre.frat@chu-poitiers.fr.

* A complete list of investigators in the Clinical Effect of the Association of Noninvasive Ventilation and High Flow Nasal Oxygen Therapy in Resuscitation of Patients with Acute Lung Injury (FLORALI) study and the Réseau Européen de Recherche en Ventilation Artificielle (REVA) Network is provided in the Supplementary Appendix, available at NEJM.org.

BACKGROUND

Whether noninvasive ventilation should be administered in patients with acute hypoxemic respiratory failure is debated. Therapy with high-flow oxygen through a nasal cannula may offer an alternative in patients with hypoxemia.

METHODS

We performed a multicenter, open-label trial in which we randomly assigned patients without hypercapnia who had acute hypoxemic respiratory failure and a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of 300 mm Hg or less to high-flow oxygen therapy, standard oxygen therapy delivered through a face mask, or noninvasive positive-pressure ventilation. The primary outcome was the proportion of patients intubated at day 28; secondary outcomes included all-cause mortality in the intensive care unit and at 90 days and the number of ventilator-free days at day 28.

RESULTS

A total of 310 patients were included in the analyses. The intubation rate (primary outcome) was 38% (40 of 106 patients) in the high-flow–oxygen group, 47% (44 of 94) in the standard group, and 50% (55 of 110) in the noninvasive-ventilation group (P=0.18 for all comparisons). The number of ventilator-free days at day 28 was significantly higher in the high-flow–oxygen group (24±8 days, vs. 22±10 in the standard-oxygen group and 19±12 in the noninvasive-ventilation group; P=0.02 for all comparisons). The hazard ratio for death at 90 days was 2.01 (95% confidence interval [CI], 1.01 to 3.99) with standard oxygen versus high-flow oxygen (P=0.046) and 2.50 (95% CI, 1.31 to 4.78) with noninvasive ventilation versus high-flow oxygen (P=0.006).

CONCLUSIONS

In patients with nonhypercapnic acute hypoxemic respiratory failure, treatment with high-flow oxygen, standard oxygen, or noninvasive ventilation did not result in significantly different intubation rates. There was a significant difference in favor of high-flow oxygen in 90-day mortality. (Funded by the Programme Hospitalier de Recherche Clinique Interrégional 2010 of the French Ministry of Health; FLORALI ClinicalTrials.gov number, NCT01320384.)
NONINVASIVE POSITIVE-PRESSURE VENTILATION (hereafter, noninvasive ventilation) reduces the need for endotracheal intubation and mortality among patients with acute exacerbations of chronic obstructive pulmonary disease or severe cardiogenic pulmonary edema. The physiological effects of noninvasive ventilation include a decrease in the work of breathing and improvement in gas exchange. In patients with acute hypoxemic respiratory failure, the need for mechanical ventilation is associated with high mortality, but data on the overall effects of noninvasive ventilation with respect to the prevention of intubation and improvement in outcome are conflicting.

Previous studies have often included a heterogeneous population of patients with acute respiratory failure who had chronic lung disease or cardiogenic pulmonary edema; this selection of patients could lead to an overestimation of the beneficial effects of noninvasive ventilation as compared with standard oxygen therapy. In observational studies focusing on patients with acute hypoxemic respiratory failure, the rate of treatment failure with noninvasive ventilation was as high as 50% and was often associated with particularly high mortality. To date, the literature does not conclusively support the use of noninvasive ventilation in patients with nonhypercapnic acute hypoxemic respiratory failure.

High-flow oxygen therapy through a nasal cannula is a technique whereby heated and humidified oxygen is delivered to the nose at high flow rates. These high flow rates generate low levels of positive pressure in the upper airways, and the fraction of inspired oxygen (FiO₂) can be adjusted by changing the fraction of oxygen in the driving gas. The high flow rates may also decrease physiological dead space by flushing expired carbon dioxide from the upper airway, a process that potentially explains the observed decrease in the work of breathing. In patients with acute respiratory failure of various origins, high-flow oxygen has been shown to result in better comfort and oxygenation than standard oxygen therapy delivered through a face mask.

To our knowledge, the effect of high-flow oxygen on intubation rate or mortality has not been assessed in patients admitted to the intensive care unit (ICU) with acute hypoxemic respiratory failure. We conducted a prospective, multicenter, randomized, controlled trial involving patients admitted to the ICU with acute hypoxemic respiratory failure to determine whether high-flow oxygen therapy or noninvasive ventilation therapy, as compared with standard oxygen therapy alone, could reduce the rate of endotracheal intubation and improve outcomes.

METHODS

STUDY OVERSIGHT

We conducted the study in 23 ICUs in France and Belgium. For all the centers in France, the study protocol (available with the full text of this article at NEJM.org) was approved by the ethics committee at Centre Hospitalier Universitaire de Poitiers; for the study site at Cliniques Universitaires Saint-Luc, Brussels, the protocol was approved by the ethics committee at that center. Written informed consent was obtained from all the patients, their next of kin, or another surrogate decision maker as appropriate.

The trial was overseen by a steering committee that presented information regarding the progression and monitoring of the study at Réseau Européen de Recherche en Ventilation Artificielle (REVA) Network meetings every 4 months. An independent safety monitoring board was set up. Research assistants regularly monitored all the centers on site to check adherence to the protocol and the accuracy of the data recorded. An investigator at each center was responsible for enrolling patients in the study, ensuring adherence to the protocol, and completing the electronic case-report form. Although the individual study assignments of the patients could not be masked, the coordinating center and all the investigators remained unaware of the study-group outcomes until the data were locked in July 2014. All the analyses were performed by the study statistician, in accordance with the International Conference on Harmonisation and Good Clinical Practice guidelines. Face masks, heated humidifiers, and cannulas (i.e., consumable materials) were donated to the participating ICUs, and air-oxygen blenders were provided during the study period, by Fisher and Paykel Healthcare, which had no other involvement in the study.
PATIENTS
Consecutive patients who were 18 years of age or older were enrolled if they met all four of the following criteria: a respiratory rate of more than 25 breaths per minute, a ratio of the partial pressure of arterial oxygen (Pao2) to the Fio2 of 300 mm Hg or less while the patient was breathing oxygen at a flow rate of 10 liters per minute or more for at least 15 minutes, a partial pressure of arterial carbon dioxide (PaCO2) not higher than 45 mm Hg, and an absence of clinical history of underlying chronic respiratory failure. Fio2 was measured by a portable oxygen analyzer (MX300, Teledyne Analytical Instruments) that was introduced in the nonrebreather face mask.

The main exclusion criteria were a PaCO2 of more than 45 mm Hg, exacerbation of asthma or chronic respiratory failure, cardiogenic pulmonary edema, severe neutropenia, hemodynamic instability, use of vasopressors, a Glasgow Coma Scale score of 12 points or less (on a scale from 3 to 15, with lower scores indicating reduced levels of consciousness), contraindications to noninvasive ventilation, urgent need for endotracheal intubation, a do-not-intubate order, and a decision not to participate. Details of the study exclusion criteria are provided in the Supplementary Appendix, available at NEJM.org.

RANDOMIZATION
Randomization was performed in permuted blocks of six, with stratification according to center and history or no history of cardiac insufficiency. Within 3 hours after the validation of inclusion criteria, patients were randomly assigned in a 1:1:1 ratio, with the use of a centralized Web-based management system (Clinsight, Ennov), to one of the three following strategies: high-flow oxygen therapy, standard oxygen therapy, or noninvasive ventilation.

INTERVENTIONS
In the standard-oxygen group, oxygen therapy was applied continuously through a nonrebreather face mask at a flow rate of 10 liters per minute or more. The rate was adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2), until the patient recovered or was intubated.

In the high-flow–oxygen group, oxygen was passed through a heated humidifier (MR850, Fisher and Paykel Healthcare) and applied continuously through large-bore binausal prongs, with a gas flow rate of 50 liters per minute and an Fio2 of 1.0 at initiation (Optiflow, Fisher and Paykel Healthcare). The fraction of oxygen in the gas flowing in the system was subsequently adjusted to maintain an SpO2 of 92% or more. High-flow oxygen was applied for at least 2 calendar days; it could then be stopped and the patient switched to standard oxygen therapy.

In the noninvasive-ventilation group, noninvasive ventilation was delivered to the patient through a face mask (Fisher and Paykel Healthcare) that was connected to an ICU ventilator, with pressure support applied in a noninvasive-ventilation mode. The pressure-support level was adjusted with the aim of obtaining an expired tidal volume of 7 to 10 ml per kilogram of predicted body weight, with an initial positive end-expiratory pressure (PEEP) between 2 and 10 cm of water. The Fio2 or PEEP level (or both) were then adjusted to maintain an SpO2 of 92% or more. The minimally required duration of noninvasive ventilation was 8 hours per day for at least 2 calendar days. Noninvasive ventilation was applied during sessions of at least 1 hour and could be resumed if the respiratory rate was more than 25 breaths per minute or the SpO2 was less than 92%. Between noninvasive-ventilation sessions, patients received high-flow oxygen, as described above.

STUDY OUTCOMES
The primary outcome was the proportion of patients who required endotracheal intubation within 28 days after randomization. To ensure the consistency of indications across sites and reduce the risk of delayed intubation, the following prespecified criteria for endotracheal intubation were used: hemodynamic instability, a deterioration of neurologic status, or signs of persisting or worsening respiratory failure as defined by at least two of the following criteria: a respiratory rate of more than 40 breaths per minute, a lack of improvement in signs of high respiratory-muscle workload, the development of copious tracheal secretions, acidosis with a pH of less than 7.35, an SpO2 of less than 90% for more than 5 minutes without technical dysfunction, or a poor response to oxygenation techniques (details of the criteria are provided in the Supplementary Appendix). In...
the high-flow–oxygen group and the standard-oxygen group, a trial of noninvasive ventilation was allowed at the discretion of the physician in patients who had signs of persisting or worsening respiratory failure and no other organ dysfunction before endotracheal intubation was performed and invasive ventilation initiated.

Secondary outcomes were mortality in the ICU, mortality at 90 days, the number of ventilator-free days (i.e., days alive and without invasive mechanical ventilation) between day 1 and day 28, and the duration of ICU stay. Other pre-specified outcomes included complications during the ICU stay, such as septic shock, nosocomial pneumonia, cardiac arrhythmia, and cardiac arrest. Dyspnea was assessed with the use of a 5-point Likert scale, and comfort with the use of a 100-mm visual-analogue scale (see the Supplementary Appendix).

STATISTICAL ANALYSIS
Assuming an intubation rate of 60% in the population that was treated with standard oxygen therapy, we calculated that enrollment of 300 patients would provide the study with 80% power to show an absolute difference of 20 percentage points in the primary outcome between the standard-oxygen group and either the high-flow–oxygen group or the noninvasive-ventilation group at a two-sided alpha level of 0.05.

All the analyses were performed on an intention-to-treat basis. Kaplan–Meier curves were plotted to assess the time from enrollment to endotracheal intubation or death and were compared by means of the log-rank test.

The treatment (standard oxygen, high-flow oxygen, or noninvasive ventilation) was introduced as two dummy variables to obtain two odds ratios or hazard ratios for comparison with the reference group, which was defined as the lowest-risk group. Variables associated with intubation at day 28 and in-ICU mortality were assessed by means of multivariate logistic-regression analyses, and those associated with mortality at 90 days were assessed by means of a Cox proportional-hazard regression analysis with the use of a backward-selection procedure. The final model included a history of cardiac insufficiency and variables significantly associated with intubation or mortality with a P value of less than 0.05.

We conducted only one post hoc subgroup analysis, which included patients with a PaO₂FiO₂ of 200 mm Hg or less at enrollment, to analyze outcomes in patients with severe hypoxemia. This threshold of the PaO₂FiO₂ was based on the classification of the acute respiratory distress syndrome.

A two-tailed P value of less than 0.05 was considered to indicate statistical significance. We used SAS software, version 9.2 (SAS Institute), for all the analyses.

RESULTS

PATIENTS
From February 2011 through April 2013, a total of 2506 patients with acute hypoxemic respiratory failure were admitted to the 23 participating ICUs; 525 patients were eligible for inclusion in the study, and 313 underwent randomization (Fig. 1). After the secondary exclusion of 3 patients who withdrew consent, 310 patients were included in the analysis. A total of 94 patients were assigned to standard oxygen therapy, 106 to high-flow oxygen therapy, and 110 to noninvasive ventilation. The median interval between randomization and the initiation of treatment was 60 minutes (interquartile range, 11 to 120).

CHARACTERISTICS AT INCLUSION
The characteristics of the patients at enrollment were similar in the three groups (Table 1). The main cause of acute respiratory failure was community-acquired pneumonia, which was the diagnosis in 197 patients (64%). Bilateral pulmonary infiltrates were present in 244 patients (79%), and 238 patients (77%) had a PaO₂FiO₂ of 200 mm Hg or less at the time of enrollment (Tables S1 and S3 in the Supplementary Appendix). The mean (±SD) baseline FiO₂, as measured through the nonrebreather face mask in 286 patients, was 0.65±0.13.

TREATMENTS
The initial mean settings were as follows: in the standard-oxygen group, an oxygen flow rate of 13±5 liters per minute; in the high-flow–oxygen group, a gas flow rate of 48±11 liters per minute, yielding a mean FiO₂ of 0.82±0.21; and in the noninvasive-ventilation group, a pressure-sup-
19,528 Patients were admitted to the ICUs in the study period, February 2011–April 2013

4777 Had acute respiratory failure

2271 Were excluded
1366 Had acute or chronic lung disease
651 Had cardiogenic pulmonary edema
155 Had contraindications to noninvasive ventilation
99 Had administrative reasons

2506 Had acute hypoxemic respiratory failure

1981 Were excluded
647 Had shock or Glasgow Coma Scale score ≤12
582 Had hypercapnia (Paco₂ > 45 mm Hg)
476 Had urgent need for intubation
180 Had do-not-intubate order
96 Had neutropenia

525 Were eligible for inclusion

212 Were excluded
160 Had logistic reasons
52 Declined to participate

313 Underwent randomization

106 Were assigned to high-flow–oxygen group

96 Were assigned to standard-oxygen group

111 Were assigned to noninvasive-ventilation group

2 Withdrew consent

1 Withdraw consent

310 Were included in the analysis and in the 90-day follow-up
106 Were in the high-flow–oxygen group
94 Were in the standard-oxygen group
110 Were in the noninvasive-ventilation group

Figure 1. Enrollment, Randomization, and Follow-up of the Study Participants.
High-flow oxygen indicates therapy with high-flow oxygen through a nasal cannula. Patients who were assigned to receive noninvasive positive-pressure ventilation (hereafter, noninvasive ventilation) received noninvasive ventilation and high-flow oxygen between sessions of noninvasive ventilation. Standard oxygen therapy was given through a nonrebreather face mask at a flow rate of 10 liters or more per minute. Patients may have had more than one reason for exclusion from the trial. Scores on the Glasgow Coma Scale range from 3 to 15, with lower scores indicating reduced levels of consciousness. ICU denotes intensive care unit, and Paco₂ partial pressure of arterial carbon dioxide.
port level of 8±3 cm of water, a PEEP of 5±1 cm of water, and an Fio2 of 0.67±0.24, resulting in a tidal volume of 9.2±3.0 ml per kilogram. Noninvasive ventilation was delivered for 8 hours (interquartile range, 4 to 12) on day 1 and for 8 hours (interquartile range, 4 to 13) on day 2.

** PRIMARY AND SECONDARY OUTCOMES **

The intubation rate at day 28 was 38% in the high-flow–oxygen group, 47% in the standard-oxygen group, and 50% in the noninvasive-ventilation group (P=0.18; P=0.17 by the log-rank test) (Fig. 2A). The intervals between enrollment

---

**Table 1. Characteristics of the Patients at Baseline, According to Study Group.**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age — yr</td>
<td>61±16</td>
<td>59±17</td>
<td>61±17</td>
</tr>
<tr>
<td>Male sex — no. (%)</td>
<td>75 (71)</td>
<td>63 (67)</td>
<td>74 (67)</td>
</tr>
<tr>
<td>Body-mass index†</td>
<td>25±5</td>
<td>26±5</td>
<td>26±6</td>
</tr>
<tr>
<td>SAPS II‡</td>
<td>25±9</td>
<td>24±9</td>
<td>27±9</td>
</tr>
<tr>
<td>Current or past smoking — no. (%)</td>
<td>34 (32)</td>
<td>36 (38)</td>
<td>40 (36)</td>
</tr>
</tbody>
</table>

Reason for acute respiratory failure — no. (%)

| Community-acquired pneumonia                        | 71 (67)                  | 57 (61)                | 69 (63)                          |
| Hospital-acquired pneumonia                         | 12 (11)                  | 13 (14)                | 12 (11)                          |
| Extrapulmonary sepsis                               | 4 (4)                    | 5 (5)                  | 7 (6)                            |
| Aspiration or drowning                              | 3 (3)                    | 1 (1)                  | 2 (2)                            |
| Pneumonia related to immunosuppression              | 6 (6)                    | 4 (4)                  | 10 (9)                           |
| Other                                               | 10 (9)                   | 14 (15)                | 10 (9)                           |
| Bilateral pulmonary infiltrates — no. (%)           | 79 (75)                  | 80 (85)                | 85 (77)                          |
| Respiratory rate — breaths/min                      | 33±6                     | 32±6                   | 33±7                             |
| Heart rate — beats/min                              | 106±21                   | 104±16                 | 106±21                           |
| Arterial pressure — mm Hg                           |                          |                        |                                  |
| Systolic                                            | 127±24                   | 130±22                 | 128±21                           |
| Mean                                                | 87±17                    | 89±15                  | 86±16                            |
| Arterial blood gas                                  |                          |                        |                                  |
| pH                                                  | 7.43±0.05                | 7.44±0.06              | 7.43±0.06                        |
| PaO2 — mm Hg                                        | 85±31                    | 92±32                  | 90±36                            |
| Fio2 ‡                                              | 0.62±0.19                | 0.63±0.17              | 0.65±0.15                        |
| PaO2:Fo2 — mm Hg                                    | 157±89                   | 161±73                 | 149±72                           |
| Paco2 — mm Hg                                       | 36±6                     | 35±5                   | 34±6                             |

* Plus–minus values are means ±SD. There were no significant differences among the study groups in any of the characteristics listed. High-flow oxygen indicates therapy with high-flow oxygen through a nasal cannula. Patients who were assigned to receive noninvasive positive-pressure ventilation (hereafter, noninvasive ventilation) received noninvasive ventilation and high-flow oxygen between sessions of noninvasive ventilation. Standard oxygen therapy was given through a nonrebreather face mask at a flow rate of 10 liters or more per minute. Fio2 denotes fraction of inspired oxygen, Paco2, partial pressure of arterial carbon dioxide, and PaO2, partial pressure of arterial oxygen.

† The body-mass index is the weight in kilograms divided by the square of the height in meters.

‡ The Simplified Acute Physiology Score (SAPS) II was calculated from 17 variables at enrollment, information about previous health status, and information obtained at admission. Scores range from 0 to 163, with higher scores indicating more severe disease.

§ Fio2 was measured in 286 patients and was estimated in the remaining patients as follows: (oxygen flow in liters per minute) × 0.3 + 0.21.
and intubation, as well as the reasons for intubation, did not differ significantly among the three groups (Table 2).

The crude in-ICU mortality and 90-day mortality differed significantly among the three groups (Table 2 and Fig. 3). The hazard ratio for death at 90 days was 2.01 (95% confidence interval [CI], 1.01 to 3.99) in the standard-oxygen
group as compared with the high-flow–oxygen group (P=0.046) and 2.50 (95% CI, 1.31 to 4.78) in the noninvasive-ventilation group as compared with the high-flow–oxygen group (P=0.006; P=0.02 by the log-rank test) (Fig. 3). The risk of death at 90 days remained significantly lower in the high-flow–oxygen group after adjustment for the baseline Simplified Acute Physiology Score II and history of cardiac insufficiency (Table 2). Four patients died in the ICU without having undergone intubation (two in the standard-oxygen group and one in each of the other two groups). The 90-day mortality among patients who required intubation did not differ significantly among the groups (Table 2). The number of ventilator-free days at day 28 was significantly higher in the high-flow–oxygen group than in the other two groups (Table 2).

In a post hoc analysis, there was a significant interaction between the PaO₂:FIO₂ at enrollment (≤200 mm Hg vs. >200 mm Hg) and the treatment group with respect to status regarding intubation (P=0.01). In the subgroup of patients with a PaO₂:FIO₂ of 200 mm Hg or less, the intubation rate was significantly lower in the high-flow–oxygen group than in the other two groups (Fig. 2B and Table 2, and Table S4 in the Supplementary Appendix). The risk of intubation remained significantly lower in the high-flow–oxygen group after adjustment for bilateral pulmonary infiltrates, respiratory rate, and preexisting history of cardiac insufficiency.

### Table 2. Primary and Secondary Outcomes, According to Study Group.  

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study Group</th>
<th>P Value†</th>
<th>Odds Ratio or Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intubation at day 28</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall population</td>
<td>0.18</td>
<td>1.45 (0.83–2.55)</td>
<td>1.65 (0.96–2.84)</td>
</tr>
<tr>
<td>No. of patients</td>
<td>40</td>
<td>44</td>
<td>55</td>
</tr>
<tr>
<td>% of patients (95% CI)</td>
<td>38 (29–47)</td>
<td>47 (37–57)</td>
<td>50 (41–59)</td>
</tr>
<tr>
<td>Patients with PaO₂:FIO₂ ≤200 mm Hg‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unadjusted analysis</td>
<td>0.009</td>
<td>2.07 (1.09–3.94)</td>
<td>2.57 (1.37–4.84)</td>
</tr>
<tr>
<td>No. of patients/total no.</td>
<td>29/83</td>
<td>39/74</td>
<td>47/81</td>
</tr>
<tr>
<td>% of patients (95% CI)</td>
<td>35 (26–46)</td>
<td>53 (42–64)</td>
<td>58 (47–68)</td>
</tr>
<tr>
<td>Adjusted analysis§</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interval between enrollment and intubation — hr¶</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall population</td>
<td>0.27</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Median</td>
<td>27</td>
<td>15</td>
<td>27</td>
</tr>
<tr>
<td>Interquartile range</td>
<td>8–46</td>
<td>5–39</td>
<td>8–53</td>
</tr>
<tr>
<td>Patients with PaO₂:FIO₂ ≤200 mm Hg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>26</td>
<td>17</td>
<td>27</td>
</tr>
<tr>
<td>Interquartile range</td>
<td>11–46</td>
<td>5–41</td>
<td>7–52</td>
</tr>
<tr>
<td>Reason for intubation — no./total no. (%)¶</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>36/51 (71)</td>
<td>43/58 (74)</td>
<td>49/67 (73)</td>
</tr>
<tr>
<td>Circulatory failure</td>
<td>7/51 (14)</td>
<td>5/58 (9)</td>
<td>5/67 (7)</td>
</tr>
<tr>
<td>Neurologic failure</td>
<td>8/51 (16)</td>
<td>10/58 (17)</td>
<td>13/67 (19)</td>
</tr>
<tr>
<td>Ventilator-free days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall population</td>
<td>24±8</td>
<td>22±10</td>
<td>19±12</td>
</tr>
<tr>
<td>Patients with PaO₂:FIO₂ ≤200 mm Hg</td>
<td>24±8</td>
<td>21±10</td>
<td>18±12</td>
</tr>
</tbody>
</table>
The rate of various complications during the ICU stay did not differ significantly among the groups (Tables S2 and S4 in the Supplementary Appendix). Among the 40 patients who received noninvasive ventilation as rescue therapy, 19 of 26 patients (73%) in the standard-oxygen group and 9 of 14 (64%) in the high-flow–oxygen group were intubated subsequently.

### PATIENT COMFORT AND SAFETY

At 1 hour after enrollment, the intensity of respiratory discomfort in the patients was reduced and the dyspnea score was improved with the use of high-flow oxygen, as compared with the other two strategies of oxygenation (Table S5 in the Supplementary Appendix). There was no significant difference among the groups in the overall...
incidence of serious adverse events. Among the 18 episodes of cardiac arrest, 3 occurred before intubation (1 in the standard-oxygen group and 2 in the high-flow–oxygen group). Two patients died during the process of intubation.

**DISCUSSION**

In this multicenter, randomized, open-label trial, neither noninvasive ventilation nor high-flow oxygen decreased the rate of intubation (the primary outcome) among patients with acute hypoxemic respiratory failure. High-flow oxygen therapy, as compared with standard oxygen therapy or noninvasive ventilation, resulted in reduced mortality in the ICU and at 90 days.

When planning the study, we assumed an intubation rate of 60% in the standard-oxygen group on the basis of data from previous randomized, controlled trials. Our results showed a lower rate than expected in the standard-oxygen group (47%) but also a higher rate than expected among patients treated with noninvasive ventilation (50%). The intubation rate in the noninvasive-ventilation group in our study is, however, consistent with the rates of 46 to 54% observed in other studies that included patients with acute hypoxemic respiratory failure. Lower rates of intubation were seen among patients with hypoxemia who were receiving high-flow oxygen therapy than among those receiving noninvasive ventilation or standard oxygen therapy.

The lower mortality observed in the high-flow–oxygen group may have resulted from the cumulative effects of less intubation particularly in the patients with severe hypoxemia (PaO$_2$/FIO$_2$ ≤200 mm Hg), as compared with other patients, and a slightly lower mortality among intubated patients who were treated with high-flow oxygen therapy than among those who were treated with one of the other strategies (Table 2). Two studies have also suggested that a failure of noninvasive ventilation might result in excess mortality, possibly because of delayed intubation, but we found no significant difference among the groups in terms of the time until intubation or the reasons for intubation. In our study, noninvasive ventilation that was administered to patients with severe lung injury could have increased the incidence of ventilator-induced lung injury by increasing tidal volumes that exceeded 9 ml per kilogram of predicted body weight. High-flow oxygen was also associated with an increased degree of comfort, a reduction in the severity of dyspnea, and a decreased respiratory

<table>
<thead>
<tr>
<th>No. at Risk</th>
<th>High-flow oxygen</th>
<th>Standard oxygen</th>
<th>Noninvasive ventilation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>106</td>
<td>100</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>94</td>
<td>84</td>
<td>93</td>
</tr>
<tr>
<td>Days since Enrollment</td>
<td>100</td>
<td>81</td>
<td>86</td>
</tr>
<tr>
<td>Days since Enrollment</td>
<td>97</td>
<td>77</td>
<td>80</td>
</tr>
<tr>
<td>Days since Enrollment</td>
<td>94</td>
<td>74</td>
<td>79</td>
</tr>
<tr>
<td>Days since Enrollment</td>
<td>94</td>
<td>73</td>
<td>78</td>
</tr>
<tr>
<td>Days since Enrollment</td>
<td>93</td>
<td>72</td>
<td>77</td>
</tr>
</tbody>
</table>

**Figure 3.** Kaplan–Meier Plot of the Probability of Survival from Randomization to Day 90.
rate. These findings might result from the heating and humidification of inspired gases, which prevented thick secretions and subsequent atelectasis but also from low levels of PEEP generated by a high gas flow rate\textsuperscript{16,17} and flushing of upper-airway dead space.\textsuperscript{20,21,23,24}

Our trial had several strengths that suggest that the results may be generalized to patients admitted for nonhypercapnic acute hypoxemic respiratory failure in other ICUs. These strengths included the multicenter design and sealed randomization to the assigned strategy, a well-defined study protocol that included prespecified criteria for intubation, complete follow-up at 90 days, and an intention-to-treat analysis.

The main limitation of our study was the low power to detect a significant between-group difference in the intubation rate in the overall population. A reduced intubation rate was detected in the post hoc analysis in the subgroup of patients with a \( \text{PaO}_2: \text{FiO}_2 \) of 200 mm Hg or less, which was justified by a significant interaction between \( \text{PaO}_2: \text{FiO}_2 \) stratum and treatment.\textsuperscript{35}

In conclusion, treatment with high-flow oxygen improved the survival rate among patients with acute hypoxemic respiratory failure, even though no difference in the primary outcome (i.e., intubation rate) was observed with high-flow oxygen therapy, as compared with standard oxygen therapy or noninvasive ventilation.

Supported by the Programme Hospitalier de Recherche Clinique Interrégional 2010 of the French Ministry of Health. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Pierre Ingrand and Bruno Giraud for reviewing the methods and statistical analysis plan, and Jeffrey Arsham for reviewing and editing an earlier version of the manuscript.

**APPENDIX**

The authors’ affiliations are as follows: Centre Hospitalier Universitaire (CHU) de Poitiers, Service de Réanimation Médicale (J.-P.F., A.W.T., C.D.-M., R.R.), and INSERM, Centre d’Investigation Clinique 1402, Université de Poitiers (J.-P.F., A.W.T., S.R., R.R.), Poitiers, CHU Angers, Service de Réanimation Médicale et Médecine Hyperbare (A.M., M.P.), CHU de Rouen, Service de Réanimation Médicale, Hôpital Charles Nicolle, and Institute for Biomedical Research and Innovation, Université de Rouen, Rouen (C.G., G.B.), CHU de Rouen, Service de Réanimation Médicale et Médecine Hyperbare, Angers (A.M., M.P.), CHU de Rouen, Service de Réanimation Médicale, Hôpital Charles Nicolle, and Institute for Biomedical Research and Innovation, Université de Rouen, Rouen (C.G., G.B.), CHU de Rouen, Service de Réanimation Médicale et Médecine Hyperbare, Angers (A.M., M.P.), CHU de Rouen, Service de Réanimation Médicale, Hôpital Charles Nicolle, and Institute for Biomedical Research and Innovation, Université de Rouen, Rouen (C.G., G.B.), CHU de Rouen, Service de Réanimation Médicale et Médecine Hyperbare, Angers (A.M., M.P.), CHU de Rouen, Service de Réanimation Médicale, Hôpital Charles Nicolle, and Institute for Biomedical Research and Innovation, Université de Rouen, Rouen (C.G., G.B.), CHU de Rouen, Service de Réanimation Médicale et Médecine Hyperbare, Angers (A.M., M.P.), CHU de Rouen, Service de Réanimation Médicale, Hôpital Charles Nicolle, and Institute for Biomedical Research and Innovation, Université de Rouen, Rouen (C.G., G.B.), CHU de Rouen, Service de Réanimation Médicale et Médecine Hyperbare, Angers (A.M., M.P.), CHU de Rouen, Service de Réanimation Médicale, Hôpital Charles Nicolle, and Institute for Biomedical Research and Innovation, Université de Rouen, Rouen (C.G., G.B.), CHU de Rouen, Service de Réanimation Médicale et Médecine Hyperbare, Angers (A.M., M.P.), CHU de Rouen, Service de Réanimation Médicale, Hôpital Charles Nicolle, and Institute for Biomedical Research and Innovation, Université de Rouen, Rouen (C.G., G.B.), CHU de Rouen, Service de Réanimation Médicale et Médecine Hyperbare, Angers (A.M., M.P.), CHU de Rouen, Service de Réanimation Médicale, Hôpital Charles Nicolle, and Institute for Biomedical Research and Innovation, Université de Rouen, Rouen (C.G., G.B.), CHU de Rouen, Service de Réanimation Médicale et Médecine Hyperbare, Angers (A.M., M.P.), CHU de Rouen, Service de Réanimation Médicale, Hôpital Charles Nicolle, and Institute for Biomedical Research and Innovation, Université de Rouen, Rouen (C.G., G.B.).

**REFERENCES**


Copyright © 2015 Massachusetts Medical Society.